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Although neuroinflammation has been studied extensively in animal models of cerebral ischemia, their contrasting
functions are still not completely understood. A major participant in neuroinflammation is microglia and microglial
activation usually regulated by the chemokine CX3CL1 (fractalkine) and its receptor, CX3CR1. Here, we examined
the involvement of CX3CR1 on ischemia-induced chronic neuroinflammation and cognitive function using small
interfering RNA (siRNA). Forty adult male Wistar rats were included in the study and received either ischemia or
sham surgery then were randomized to receive either CX3CR1 siRNA or scrambled RNA as control starting at 7 days
after reperfusion. Behavioral testing commenced 28 days after siRNA delivery and all rats were euthanized after
behavioral testing. Our data showed that: (i) transient global cerebral ischemia significantly decreased fractalkine/
CX3CR1 signaling in the hippocampus; (ii) inhibition of CX3CR1 function exacerbated the ischemia-induced chronic
increase in microglial activation and pro-inflammatory cytokine levels; (iii) inhibition of CX3CR1 function worsened
ischemia-induced chronic cognitive impairment; (iv) inhibition of CX3CR1 function in sham rats resulted in increased
IL-1β expression and impaired behavioral performance. However, no significant effect of CX3CR1 on ischemia-induced
neurodegeneration was seen. The present study provides important insight to understanding the involvement of
CX3CR1 in chronic neuroinflammation and cognitive impairment.
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RIschemic brain injury is, in part, an inflammatory disease.The pathophysiology of cerebral ischemia includes a se-quence of events that involves the actions of several cen-
tral and peripheral cell types as well as a large number of
inflammatory molecules [1,2]. For example, postischemic
acute inflammatory cascade reported in experimental and
clinical conditions involves the upregulation of intercellu-
lar adhesion molecules [3], activation of microglia, and the
upregulation and release of cytokines [4]. This cascade of
events participates in the complex linking of signaling
pathways that can ultimately upregulate or downregulate
the inflammatory-mediated host response to injury. It is
clear that the central nervous system (CNS) is capable of
mounting a sustained and robust inflammatory response
in conditions such as cerebral ischemia but the complexR
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stated.role of neuroinflammation following ischemic injury re-
mains an area of debate.
The question whether neuroinflammation is destructive
and/or beneficial following ischemic injury has been de-
bated for a long time but the answers remain equivocal. A
major participant in the neuroinflammatory process is
microglia since these cells are among the first to display
very early activation in ischemic injury and are capable of
contributing to neuronal damage by expressing potentially
harmful molecules, such as interleukin-1β (IL-1), tumor
necrosis factor-α (TNF-α), and reactive oxygen species [5].
However, microglia can also provide protective effects in
ischemic injury and participate in restoring damaged tis-
sues (repair function) by engulfing neutrophils [6], and
through the release of growth factors [7] and anti-
inflammatory cytokines such as IL-4 and IL-10. Although
the processes of microglial activation, proliferation, cyto-
kine production, and phagocytosis have been studiedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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extensively in animal models of cerebral ischemia, their
contrasting functions are still not completely understood.
Among the molecules that regulate microglial activation
is the chemokine CX3CL1 (fractalkine), which is constitu-
tively expressed by normal neurons. CX3CL1 signals
to microglia by binding to only one receptor, CX3CR1,
whose function is to inhibit microglial activity [8,9]. In the
brain, the CX3CR1 receptor is exclusively expressed by
microglia [8] and when neuronal damage occurs, fractalk-
ine levels decrease in the immediate hours after injury,
which then decreases CX3CR1 receptor signaling result-
ing in the recruitment and activation of microglia [10].
Over the last few years, there has been increasing interest
in the role of fractalkine in central nervous system injury.
For example, the importance of the fractalkine/CX3CR1
pathway in neurological disorders has been assessed using
an animal model wherein the cx3cr1 gene is substituted
with the gene for the green fluorescent protein (GFP) pro-
ducing a defective receptor for fractalkine [11]. Using this
animal model, studies on lateral amyotrophic sclerosis
[12], Parkinson’s disease [13], and Alzheimer’s disease [14]
report that the absence of CX3CR1 is associated with a
worse outcome possibly due to the lack of fractalkine con-
trol of microglial activation leading to chronic proinflam-
matory function [15]. However, others also report that in
transient and permanent ischemia as well as spinal cord
injury, absence of CX3CR1 result in favorable outcome
after injury [16-18]. These conflicting data to date do not
provide a coherent picture on the role of fractalkine in
brain injury and disease. Moreover, little information is
available on fractalkine/CX3CR1 signaling in the context
of persistent neuroinflammation as a chronic consequence
of transient global cerebral ischemia. We hypothesize the
direct involvement of CX3CR1 functioning in ischemia-
induced persistent neuroinflammation and cognitive im-
pairment. Here, we study the role of CX3CR1 on transient
global cerebral ischemia-induced chronic neuroinflamma-




Male Wistar rats (body weight, 350–375 g at the time of
surgery) were obtained from Harlan Laboratories (Madison,
WI, USA). Animals were housed in pairs in a pathogen-free
vivarium under controlled condition (temperature, 22 ±
1°C; humidity, 70 ± 5%) and a 14:10-h light:dark cycle
was maintained. All animals were housed in the same
room so that temperature, humidity, and lighting condi-
tions were similar for all groups. Animals had free access
to food and water delivered through an automated and fil-
tered system. Animals were also handled daily throughout
the study so that they could get acclimated to the research
personnel thereby decreasing stress. Experiments started 1AC
TE
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week after arrival of the animals from the breeder and all
protocols in this study were approved by the Institutional
Animal Care and Use Committee and in accordance with
the National Institutes of Health guidelines.
Cerebral ischemia
The four-vessel occlusion method was used to induce
transient global cerebral ischemia as described previously
[19]. Briefly, rats were anesthetized with isofluorane/oxy-
gen (2.5% isofluorane and 30% oxygen) mixture and both
common carotid arteries were isolated. Immediately fol-
lowing isolation of both carotid arteries, the vertebral ar-
teries were electrocauterized. Body temperature was kept
at 37°C to 37.5°C using a heating pad during the surgical
procedure and until the animals were fully recovered. The
next day, both common carotid arteries were occluded for
12 minutes while the animals were awake. Animals that
developed postoperative complications such as excessive
weight loss (>20% of preoperative body weight, n = 0) were
excluded from the study. In addition, observing for slug-
gishness, extreme aversion to being touched, and weight
loss assessed pain level. Animals were not given postoper-
ative analgesia but were euthanized immediately when
persistent pain was observed (n = 0). Sham-operated ani-
mals were subjected to the same anesthesia and surgery
that consisted of a neck incision without carotid manipu-
lation and an incision behind the occipital bone without
cauterization of the vertebral arteries. All efforts were
made to minimize animal distress and reduce the number
of rats used.
SiRNA delivery
Synthesized CX3CR1 siRNA or scrambled RNA was de-
livered to the left ventricle (−0.9 mm anteroposterior,
1.6 mm lateral, 4 mm deep) using the coordinates ac-
cording to Paxinos and Watson [20] taking into consid-
eration the predictable ventricular shifts after ischemic
injury [21]. CX3CR1 siRNA (product # sc-39905) and
scrambled RNA (control; product # sc-37007) were de-
signed and synthesized by Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Miniosmotic pump was used
for continuous delivery of the siRNA or scrambled RNA
that was dissolved in the transfection medium (3 mL,
Santa Cruz Biotechnology). Anesthetized animals (con-
tinuous isofluorane inhalation) were immobilized on a
stereotaxic apparatus and a guide cannula (Brain Infu-
sion kit 2; Durect Company, Cupertino, CA, USA) was
implanted in the right cerebral ventricle and stabilized
using dental cement. The cannula was then attached to the
miniosmotic pump (Alzet Model 1002, Durect Company),
which was inserted subcutaneously through a midscapular
incision, and a constant rate of infusion (0.5 μL/h; total vol-
ume 100 μL and 5 nmol concentration) was maintained.
The miniosmotic pump was primed in sterile normal saline
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bath (37°C) overnight before insertion. Cannula implant-
ation and drug delivery started 7 days after surgery wherein
rats from the ischemic and sham groups were randomly
assigned to received either CX3CR1 siRNA (n = 10 sham
and n = 10 ischemia) or scrambled RNA (n = 10 sham and
n =10 ischemia). The drug was delivered for 28 days
followed by behavioral testing (Figure 1). The stereotaxic
coordinates [20,21] and dose of infusion used were based
on previous reports [22,23] and our preliminary data. Effi-
cacy of CX3CR1 siRNA was determined by quantifying
CX3CR1 messenger RNA (mRNA) level and protein ex-
pression in the hippocampus.
Behavioral testing
Rats were tested in three versions of the water maze and
the tub was filled with tepid water (22 ± 2°C) and made
opaque by the addition of powdered milk. In the cued
learning task, the pool was divided into four quadrants
of equal surface area and the starting locations for testing
were assigned north, south, east, and west (not actual
compass positions but rather relative to the behavioral
testing room). The behavioral testing walls were already
painted white so just the other distal (to the water maze)
visual cues in the rooms were removed during the ha-
bituation training and actual testing. The cued spatial
learning and memory (acquisition and recall) task is
sensitive to hippocampal dysfunction [24]. The day be-
fore actual testing started, rats were given habituation
training for the purpose of teaching the rats to swim
and locate the platform using the visible cue. Habitu-
ation training consisted of allowing the rats to swim to
locate a visible goal, which is a 10 cm diameter flower
pot positioned in one quadrant halfway between the
center and the side of the pool and submerged 2 cm
below the surface with a small brass rod mounted on it
vertically protruding 10 cm above the water with a red
plastic ball mounted at the top as a visual cue. The day
of habituation training, rats received four trials with the
goal/platform in a fixed location and fixed starting loca-
tion (start position is east quadrant and the platform lo-
cated in the west quadrant). Testing was conducted the
day after completion of the habituation training, wherein
the rats received three trials per day for 4 consecutive daysR
Figure 1 Timeline. Study timeline. Legends: D: day; DNMT: delayed non-mAC
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and the starting location and visual goal positions were
changed randomly for every trial. During the trials, swim
latency (time to reach the platform) to reach the platform
was recorded by a video camera connected to an image
analyzer (Water Maze System Version 4.20, Columbus,
OH, USA). In addition, swimming speed (path length/
swim latency) was used to assess the motoric activity in
performing the task.
Water maze discrimination learning task
The rats were tested in the discrimination-learning test
after 2 days of rest following the cued learning and mem-
ory task. The discrimination-learning task is also sensitive
to non-hippocampal dysfunction [25]. Rats were given
four trials per day for 4 days and had to discriminate be-
tween black and white visible goals to find the hidden
platform and all extra-maze cues in the room were again
covered. The goal painted white was placed on top of the
hidden platform to provide escape (P+) from the water (lo-
cated in the southeast quadrant); whereas the other one
painted black was floating (P-) and not able to offer suffi-
cient buoyancy to support the rat (located in the south-
west quadrant). Both visible goals were placed 10 cm
above the water level. For this task, path taken to reach
the correct goal was recorded as well as search errors
based on the choices of P+ compared to P- since the aim
was to train the rats to avoid P-. Search errors represent
the number of P- choices made during the daily trials.
Delayed non-matching-to-sample task
This task consisted of a series of paired sample and test
trials using cylindrical objects as visible cues that are
suspended directly above the submerged platform in the
water maze. At the beginning of each sample trial, either
a black or white cylinder was suspended directly above
the submerged platform in the water maze. In subse-
quent test trials, both cylinders were present but the cy-
linder not present during the preceding sample trial was
suspended over the platform and served as a cue for the
location of the goal. Thus, if on a given sample trial, the
black cylinder cued the platform, and then on the suc-
ceeding test trial, the white cylinder was used to cue the
platform. The black and white cylinders were selected asatching-to-sample; Sx: sham or ischemia surgery.
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sample stimuli for each pair of trials according to a
semi-random schedule that ensured each cylinder served
as the sample stimulus on 50% of the trials over the
phase of the experiment. For each test trial, the platform
was moved to another quadrant with the non-sample cy-
linder located directly above it while the sample cylinder
was moved to a different quadrant. Based on a random
schedule, the position of the submerged platform was
changed after each sample and test trial to eliminate the
use of spatial cues. All quadrants were used equally for
locating cues in the sample and test trials and the plat-
form was positioned randomly. The day before testing,
rats were allowed a habituation swim for 10 s without
the submerged platform.
At the beginning of each sample trial, the rat was
placed in the pool at the same location (in the center of
the south-east quadrant), facing the wall of the pool, and
allowed to swim to the submerged platform under the
sample cylinder. The rat was allowed to remain on the
platform for 10 s. If the rat failed to find the platform
within 60 s, it was picked up and placed on the platform
for 10 s then removed and placed under a heat lamp
while the platform is moved and the cylinders put in
position for the test trial. The heat lamp allowed for the
rats to get dry before the test trial. Getting the cylinders
and platform ready for the test trial took approximately
10 s. Rats received four pairs of sample and test trials
per day for 4 days and the paired sessions were con-
ducted with intervals of 60, 90, 120, or 180 s delay be-
tween the sample and test trials (the intervals do not
include the 10 s required for repositioning the cylinders
and platform). The order of the delays varied each day
according to a random schedule.
Tissue preparation
The day after the completion of behavioral testing, all
rats were euthanized using CO2 inhalation and the
brains were removed and cut in half sagitally. Half of the
brain was immediately placed in liquid nitrogen until
processed and used for western blot, real-time polymer-
ase chain reaction, and ELISA. The other half was used
for Fluoro-Jade staining and immunohistochemistry. For
immunohistochemistry and Fluoro-Jade, brains were
fixed in 4% paraformaldehyde in 0.1 M phosphate buffer,
pH 7.3 overnight then cryoprotected before sectioning.
Immunohistochemistry
The fixed brains were sectioned at 30 μm thickness
using a cryostat and the free-floating method was used
as described previously [26]. Briefly, tissue sections were
first treated with 0.3% hydrogen peroxide in PBS then
placed in the blocking solution of 3% serum, 0.1%
Triton-X, and 1% bovine serum albumin for 1 h (pH 7.3)
followed by incubation for 48 h at 4°C with antibodyAC
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recognizing microglia: (1) ED-1 (1:1,000; mouse mono-
clonal; Serotec, Raleigh, NC, USA), or (2) OX-42 (mouse
monoclonal; 1:500; Cell Signaling, Billerica, MA, USA).
The primary antibodies were detected using biotinylated
IgG secondary antibodies (1:200; Vector Laboratories,
Burlingame, CA, USA) for 1 h at room temperature fol-
lowed by incubation in avidin-biotin complex (ABC kit,
Vector Laboratories, Burlingame, CA, USA). Immunor-
eactions were visualized with hydrogen peroxide and
3,3’-diaminobenzidine tetrahydrochloride (DAB) in Tris
buffer (pH 7.3) enhanced with nickel then mounted on
gelatin-coated slides, dried, and coverslipped. Tissues
from all experimental groups were run simultaneously
and under identical conditions to ensure reproducibility
of results. A pre-dilution test was done to ensure specifi-
city of the antibody and negative controls, involving de-
letion of the primary antibody, were used to rule out any
non-specific interactions. The unbiased stereological
method of area-fractionation was used to quantify im-
munoreactivity with the counting grid defined by the
StereoInvestigator (MicroBrightfield, Colchester, VT,
USA) computerized analysis system as described previ-
ously [26]. The percentage of coverage in four sections
was averaged to obtain a final estimate of microglial
immunoreactivity for each animal.
Western blot
To assess CX3CR1 expression, 0.5 g of frozen hippo-
campal tissue from each rat was used for western blot.
Briefly, tissues were homogenized in extraction buffer
(50 mM Tris, pH 8.0), 150 mM NaCl, 5 mM EDTA, pro-
tease inhibitor mixture (Sigma, St. Louis, MO, USA), and
100 mM phenylmethylsulfonyl fluoride (Sigma Aldrich)
then the homogenates were centrifuged at 10,000 × g for
10 min, and the supernatants were collected. Total protein
concentration was determined using the BCA-Protein
assay (Pierce, Rockford, IL, USA). The supernatant was
boiled for 5 min at 95°C, and stored at −20°C until use.
For western blot, equal amounts of protein (40 μg) from
each rat were loaded and separated by SDS-PAGE
gel electrophoresis as previously described [26]. Briefly,
the protein bands were electrophoretically separated
then transferred to nitrocellulose membranes (Amersham,
Piscataway, NJ, USA). The membranes were stained with
0.5% Ponceau S to assure equal total protein loading, then
destained and non-specific binding sites were blocked by
incubation of the membranes in 5% powdered milk in
Tris-buffered saline containing 0.5 ml/L Tween-20. After
blocking, membranes were incubated overnight at 4°C
with: (1) anti-CX3CR1 (1:1,000, polyclonal rabbit), (2)
anti-fractalkine (1:1,000, polyclonal goat), or (3) anti-β-
actin (1:2,000, polyclonal rabbit) with gentle agitation.
All primary antibodies were obtained from Santa Cruz
Biotechnology. Immunocomplexes were visualized using
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horseradish peroxidase-conjugated secondary antibodies
(Sigma Aldrich) and chemiluminescence (Pierce, Rockford,
IL, USA). Samples were analyzed in triplicates and mea-
surements were averaged and used as one individual data
point for statistical analysis. Quantification was done by
densitometric analysis (ImageJ v.1.47) using actin as an in-
ternal control.
ELISA
The Quantikine Rat Specific ELISA kit (R&D Systems
Inc., Minneapolis, MN, USA) was used to determine IL-
1β, TNF-α, IL-4, and IL-10 protein expression. ELISA was
performed according to the manufacturer’s instructions.
Briefly, 0.5 g of frozen hippocampal tissue from each rat
was homogenized with a glass homogenizer in 1 mL buf-
fer containing 1 mmol/L phenylmethylsulfonyl fluoride,
1 mg/L pepstatin A, 1 mg/L aprotinin, and 1 mg/L leu-
peptin in PBS (pH 7.2) and centrifuged at 12,000 × g for
20 min at 4°C. The supernatant was collected and total
protein was determined. Standards, controls, and samples
(50 μL) were pipetted into a 96-well plate precoated with
polyclonal antibodies specific for IL-1β, TNF-α, IL-4, and
IL-10, then incubated at room temperature for 2 h on an
orbital plate shaker (approximately 250 rpm) then washed
5× before adding the conjugate. After several washes, the
chromogen (tetramethylbenzidine) was added to each well
and incubated for an additional 30 min. Color reaction
was stopped by an equal volume of stop solution and reac-
tion was read in a microplate reader (Bio-Tek, Winooski,
VT, USA) at a wavelength of 450 nm (650-nm reference
wavelength). The color change was proportional to the
concentration of the cytokines measured and all samples
measured within the range of the standard curve. Assays
were sensitive to 1.5 pg/mL of IL-1β, 5 pg/mL of TNF-α,
5 pg/mL of IL-4, and 10 pg/mL of IL-10; and inter- and
intra-assay coefficients of variation were <10%.
Real-time polymerase chain reaction (RT-PCR)
To examine mRNA expression of CX3CR1, RT-PCR was
used. After 0.2 g of frozen hippocampal tissue was ho-
mogenized in Trizol (Invitrogen, Carlsbad, CA, USA),
total RNA was extracted using an RNeasy extraction kit
(Qiagen, UK) according to the manufacturer’s protocol.
From the RNA, cDNA was synthesized with CX3CR1
primers (forward 5′-CTACACAAGCGAGGGAGAGG-
3′; reverse 5′-TGGTCCGTATTTCTTGCACA-3′) and
GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
primers (forward 5′-AGACAGCCGCATCTTCTTGT-
3′; reverse 5′-CTTGCCGTGGGTAGAGTCAT-3′) at
50°C using the SuperScript III First-Strand Synthesis
(MBI Fermentas, Glen Burnie, MD, USA) following the
manufacturer’s instructions. After reverse transcription,D
the cDNA was diluted and the sample was amplified by
RT-PCR (LightCycler, Roche Diagnostics, Idaho Falls, ID,
USA) using SYBR Green master mix or TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA,
USA) and the following cycling parameters were used: ini-
tial denaturation and enzyme activation at 95°C, followed
by 45 cycles of denaturation at 95°C, and extension at
72°C. Copy numbers of CX3CR1 transcripts were nor-
malized against those of GAPDH (housekeeping gene)
transcripts for each sample. All reactions were performed
in triplicate. For quantitative analysis of target gene
mRNA, the comparative threshold cycle (CT) method
was used [27]. The difference between the normalized
threshold cycle for the ischemia and sham samples were
expressed as fold change.TEStatistical analysisAll experimental protocols were coded to preclude experi-menter bias. The SAS statistical program was used foranalysis and error bars indicate ± standard error of themean in the sample used in the study.
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Results
The main goal of the study was to determine the involve-
ment of CX3CR1 in ischemia-induced chronic neuroinflam-
mation and cognitive impairment using siRNA technology.
First, we evaluated fractalkine expression and found signifi-
cantly decreased expression in the hippocampus of ischemic
rats (F(3,36) = 7.34, P <0.05) compared to the sham groups
(Figure 2A). But no significant difference was seen in frac-
talkine expression between the ischemic groups. As well,
no significant difference was seen in fractalkine expression
in the sham groups. For the present study, non-viral de-
livery of siRNA was chosen for selective inhibition of
CX3CR1 signaling to avoid the developmental caveats that
can be associated with the use of knockout mice. Also,
transfection reagents for delivery of CX3CR1 siRNA en-
ables substantially lower doses and potentially less fre-
quent dosing [28]. We validated the efficacy of our siRNA
delivery system using RT-PCR and western blot and our
results showed significantly decrease levels of CX3CR1
gene (F(3,36) = 12.11, P <0.05) and protein expression
(F(3,36) = 11.04, P <0.05) in the hippocampus of rats that
received the CX3CR1 siRNA (Figure 2B and C) compared
to rats given the scrambled RNA (control) suggesting that
we were able to effectively inhibit CX3CR1 expression.
Both ischemia and sham rats that received the siRNA
showed 71% and 78% decrease in CX3CR1 gene expres-
sion compared to the ischemia control and sham control
group, respectively. Post-hoc comparisons showed that is-
chemic control rats also showed decrease CX3CR1 com-




Figure 2 Transient global cerebral schemia decreases fractalkine/CX3CR1 Expression. (A) Decreased fractalkine expression was detected in
the hippocampus of ischemic rats in comparison to the sham animals. Upper panel shows representative western blot. (B) Real-time polymerase
chain reaction was used to validate the efficacy of siRNA delivery by measuring CX3CR1 mRNA in the hippocampus. Both ischemia and sham rats
that received the siRNA showed significant decrease in CX3CR1 gene expression compared to the ischemia control and sham control groups,
respectively. But ischemic control rats also showed decrease CX3CR1 gene expression when compared to the sham control animals. (C) Similar
pattern of expression was seen when CX3CR1 protein was evaluated as seen in both the bar graph and representative western blots (upper
panel). Legends: 1: ischemia/siRNA; 2: ischemia/control; 3: sham/siRNA; 4: sham/control. *P <0.5 and **P <0.01.
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cytokines on ischemia-induced chronic neuroinflammation.
For this purpose, ischemic and sham rats were given either
CX3CR1 siRNA or scrambled RNA as control continu-
ously via osmotic pump starting at 7 days after reperfusion
and behavioral testing commenced 28 days after. We then
examined hippocampal tissues for microglial expression
and levels of IL-1β, TNF-α, IL-4, and IL-10. Our results
indicated that ischemic rats had significantly increased
number of immunoreactve cells that express the micro-
glial markers OX-42 and ED1 (F(3,36) = 10.91, P <0.05) and
(F(3,36) = 12.31, P <0.05), respectively, in comparison to the
sham animals (Figure 3A and B). OX-42 is a marker for
constitutively expressed microglia and its upregulation is
usually the first index of microglial activation while ED-1
is a marker for phagocytic microglia. The presence of bothOX-42 and ED-1 immunoreactive cells were widespread
in the hippocampal region of ischemic animals compared
to a few staining evident in the sham groups. However,
the number of OX-42 and ED1 immunoreactive cells dif-
fered between the two ischemic groups in that, level of
OX-42 was significantly higher in the ischemia control
when compared to the ischemic rats with deficient
CX3CR1 function (F(3,36) = 7.55, P <0.05). Conversely, level
of ED1 positive cells was significantly higher in the ische-
mia CX3CR1 deficient rats compared to the ischemia con-
trol group (F(3,36) = 8.22, P <0.05).
Analysis of activated microglia showed three cellular
phenotypes corresponding to activation state: ramified
(resting), hypertrophic and bushy (activated), and ameb-
oid (highly activated). Ramified microglia have small cell
bodies, and thin, long and highly branched processes. In
contrast, hypertrophic and bushy microglia have larger
cell bodies, with thicker and shorter processes that form




Figure 3 Cerebral ischemia and CX3CR1 deficiency increased microglial activation in the hippocampus. (A) Significantly increased
phagocytic microglia was detected in ischemic rats with CX3CR1 deficiency in comparison to the sham rats and the ischemic control animals.
Expression of phagocytic microglia was also significantly increased in the ischemic control rats in relation to the sham group with the greatest
increased seen in the CX3CR1 deficient rats. In contrast, the number of ED1-positive cells in the sham rats was negligible and no group difference
was seen. Upper panel shows representative photomicrograph of ED1 staining showing larger cell bodies and very short processes. (B) Significantly
increased OX-42 microglia phenotype was detected in ischemic control rats compared to the ischemic animals with CX3CR1 deficiency and sham
groups. OX-42-positive cells were also significantly increased in ischemic animals with CX3CR1 deficiency in comparison to the sham groups. The
number of OX-42-positive cells in the sham rats was negligible and no group difference was seen. Upper panel shows representative photomicrograph
of OX-42 staining showing large cell bodies and short processes. (C) Representative photomicrographs of the different microglial phenotype. Ramified
microglia or ‘resting microglia’ have smaller cell bodies and longer processes while hypertrophic microglia, also considered as moderately activated,
shows bushy appearance, larger cell bodies, and shorter processes. Meanwhile, the ameboid phenotype, considered as highly activated, shows large
cells bodies with almost no processes evident. Scale bar = 100 μm. (D) When microglial phenotype was quantified, the ‘resting’ form was significantly
increased in the sham groups compared to the ischemic animals but microglial activation was seen in both ischemic groups. The hypertrophic
phenotype (E) was significantly increased in the ischemia control rats while expression of the (F) ameboid phenotype was significantly higher
in the ischemic animals with CX3CR1 deficiency. The number of hypertrophic and ameboid microglial phenotype in the sham groups were
negligible. *P <0.05 and **P <0.01.
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crease number of ramified characteristics in the sham
groups (F(3,36) = 7.81, P <0.05) compared to the ischemia
animals (Figure 3D). Hypertrophic and bushy phenotype
was significantly increased in the ischemia control rats
(F(3,36) = 8.33, P <0.05) compared to the ischemic group
with deficient CX3CR1 function (Figure 3E). On the
other hand, significantly increased number of ameboid
microglia phenotype (F(3,36) = 11.62, P <0.05) was evident
in the ischemic rats with deficient CX3CR1 function
(Figure 3F).
Quantification of cytokine levels via ELISA was used to
assess the functional state of microglia. Our results
showed significantly different expression between IL-1β,
TNF-α, IL-4, and IL-10. Post-hoc comparison showed that
levels of the proinflammatory cytokines IL-1β (F(3,36) =8.10, P <0.05) and TNF-α (F(3,36) = 10.93, P <0.05) were
significantly elevated in the ischemic rats given the
CX3CR1 siRNA when compared to the ischemic control
group (Figure 4A and B). Post-hoc comparisons also
showed significantly increase IL-1β but not TNF-α in
sham animals given CX3CR1 siRNA compared to the
sham control group while IL-1β expression in the sham
rats given CX3CR1 siRNA is similar to the ischemia
control group. When anti-inflammatory cytokines IL-4
(F(3,36) = 7.44, P <0.05) and IL-10 (F(3,36) = 8.13, P <0.05)
were assessed, we found significantly increased expression
in the ischemic control group compared to the rats with
ischemic rats with deficient CX3CR1 function (Figure 4C
and D). No significant difference was seen in IL-4 and
IL-10 levels in the sham groups. Since increased levels
of pro-inflammatory cytokines has been associated with
‘classically activated’ microglia while expression of anti-
inflammatory cytokines has been associated with ‘alter-
natively activated’ microglia [5], these results suggest a
CT
ED
Figure 4 Cytokine expression in transient global cerebral ischemia and CX3CR1 deficiency was detected using ELISA. (A) Significant
increase in IL-1β expression was seen following transient global cerebral ischemia, which was amplified by CX3CR1 deficiency. Silencing of
CX3CR1 function in sham rats also resulted in increased IL-1β expression. (B) Expression of TNF-α also increased significantly following ischemic
injury and intensified by CX3CR1 deficiency. Low level TNF-α expression was seen in the sham animals and no significant group difference was
seen. (C) Ischemic injury also significantly elevated the expression of the anti-inflammatory cytokine IL-4 but the upregulation was mitigated by
CX3CR1 deficiency. Low level IL-4 expression was seen in the sham animals and no significant group difference was seen. (D) Similarly, IL-10
expression significantly increased after ischemic injury but the upregulation was mitigated by CX3CR1 deficiency. Low level IL-10 expression was
seen in the sham animals and no significant group difference was seen. *P <0.05 and **P <0.01.
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direct involvement of CX3CR1 in regulating the inflam-
mation state of activated microglia following transient
global cerebral ischemia.
CX3CR1 deficiency in the hippocampus and ischemia-
induced delayed neurodegeneration
Histological evaluation showed no FluoroJade staining in
the hippocampal tissues of the sham animals. However,
FluoroJade-positive cells were present in both ischemic
group and staining was confined to the CA1 sector of
the dorsal hippocampus. Quantification of FluoroJade-
positive cells in the ischemic group showed no significant
difference (F(3,36) = 2.93, P = 0.21) between the ischemia
control rats and the ischemia group with deficient
CX3CR1 function (Figure 5). These results suggest that in-
hibition of CX3CR1 signaling days after 7 days of reperfu-
sion did not have any effect on ischemia-induced delayed
neurodegeneration.
CX3CR1 deficiency worsens ischemia-induced cognitive
impairment
We also aimed at evaluating the role of CX3CR1 signal-
ing on ischemia-induced cognitive impairment using
three versions of the water maze test with varying diffi-
culty and habituation test was given before starting each
behavioral task. In the first version, the cued learningAtask was used wherein rats were trained to locate thegoal using a visible cue. Analysis of behavioral perform-
ance in the cued learning test showed significant main
effects of ischemia (F(3,36) = 7.82, P <0.05) and CX3CR1
(F(3,36) = 7.95, P <0.05) where both ischemic groups had
increased mean swim latency and frequently took the in-
direct route to reach the goal compared to the sham
control animals. Post-hoc comparisons showed that the
ischemic rats given the CX3CR1 siRNA were more im-
paired in performing the cued learning task compared to
the ischemia control group (Figure 6A). Meanwhile, per-
formance of the sham animals given CX3CR1 siRNA
showed significant impairment in the cued learning task
when compared to the sham control group. No signifi-
cant difference was seen in the performance of the sham
rats given CX3CR1 siRNA to that of the ischemia con-
trol group. No significant interaction effect (F(3,36) = 3.14,
P = 0.19) was seen between ischemia and CX3CR1. These
results suggest that CX3CR1 deficiency in both physio-
logic and pathologic conditions can induce cognitive
impairment on hippocampal-dependent tasks.
On the second version of the water maze task, rats
were tested in discrimination learning where they need
to distinguish the difference between the correct versus
the incorrect visible goals in the water maze. Significant
increase in mean swim latency (F(3,36) = 7.90, P <0.05)
EDFigure 5 Evaluation of ischemia-induced neurodegeneration using Fluoro-Jade staining. Representative photomicrographs of FluoroJadestaining are shown in the upper panel. FluoroJade staining was confined to the CA1 region of the hippocampus. Scale bar = 50 μm. No
significant difference in the number of FluoroJade-positive cells between the ischemic control and ischemic CX3CR1 deficient rats.
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was seen in the ischemic groups because they most often
took the path to the incorrect goal compared to the sham
control group while the ischemic group given CX3CR1
siRNA had the worst performance overall. Post-hoc com-
parison showed that performance of sham rats given
CX3CR1 siRNA in the discrimination learning task was
significantly impaired when compared to the sham control
group but not significantly different from the ischemia
control animals. No interaction effect (F(3,36) = 3.01,
P = 0.17) was seen between ischemia and CX3CR1
(Figure 6B). Analysis of the number of errors made by the
rats in locating the correct goal showed that the ischemic
rats regularly chose P- (the incorrect goal) in most of the
trials compared to the sham control group but ischemic
animals given CX3CR1 siRNA made the most errors
in (F(3,36) = 7.19, P <0.05) identifying the correct goal
(Figure 6C). Post-hoc comparison showed that error rate
in the sham rats given CX3CR1 siRNA was significantly
higher in comparison to the sham control group but not
significantly different from the ischemia control animals.
No interaction effect (F(3,36) = 4.30, P = 0.10) was seen
between ischemia and CX3CR1. Together, these results
suggest that deficiency in CX3CR1 signaling can result in
cognitive impairment in the discrimination learning task
for both intact and injured animals.
In the third version of the water maze test, rats were
tested in the delayed non-matching-to-sample task con-
sisting of a sample and test trials and a time delay in bet-
ween trials. Our results showed significant main effect of
ischemia (F(3,36) = 8.02, P <0.05) as well as a significant
main effect of CX3CR1 (F(3,36) = 8.75, P <0.05) in that is-
chemic rats demonstrate significantly increased mean
swim latency exacerbated by CX3CR1 deficiency; andAC
Tsilencing of CX3CR1 function in the sham animals also
resulted in longer mean swim latency (Figure 6D). As well,
significant main effect of ischemia (F(3,36) = 9.71, P <0.05)
and CX3CR1 (F(3,36) = 10.23, P <0.05) were seen in error
rate wherein ischemic rats and sham animals with
CX3CR1 deficiency made more errors in the delayed non-
matching-to-sample task when compared to the sham
control group; however, ischemic rats that received the
CX3CR1 siRNA showed the worst performance overall
(Figure 6E). Post-hoc comparison showed that perform-
ance of sham rats given CX3CR1 siRNA in the delayed
non-matching-to-sample task was similar to the ischemia
control group. We also found that the number of errors
made in the delayed non-matching-to-sample task in-
creased with increasing time delay between the sample
and test trials. No interaction effect (F(3,36) = 3.23, P = 0.14)
was seen between ischemia and CX3CR1. These results
suggest that CX3CR1 deficiency in both intact and injured
animals can result in impaired performance in the non-
hippocampal-dependent cognitive task.
Discussion
In this study, we demonstrate that CX3CR1 function is in-
volved in regulating the chronic neuroinflammation and
cognitive impairment induced by transient global cerebral
ischemia. These findings are supported by our data that: (i)
transient global cerebral ischemia significantly decreased
fractalkine/CX3CR1 signaling in the hippocampus; (ii)
inhibition of CX3CR1 function exacerbates the ischemia-
induced chronic increased in microglial activation and
pro-inflammatory cytokine levels; (iii) inhibition of CX3CR1
function worsens ischemia-induced chronic cognitive im-






Figure 6 CX3CR1 deficiency cause cognitive impairment. Transient global cerebral ischemia resulted in increased mean swim latency in the
cued learning task (A), discrimination learning task (B), and delayed non-matching-to-sample task (D) compared to the sham control group.
Ischemic rats also made more error in the discrimination learning task (C) and delayed non-matching-to sample task (E) when compared to the
sham control animals. However, CX3CR1 deficiency in the ischemic rats exacerbated their impaired behavioral performance in the cued learning,
discrimination learning, and delayed non-matching-to-sample task. CX3CR1 deficiency in the sham rats also resulted in impaired behavioral
performance in the three cognitive tasks.*P <0.05 and **P <0.01.
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behavioral performance. However, our results show no
significant effects of CX3CR1 deficiency on ischemia-
induced neurodegeneration in the hippocampus, which
are at odds with previous reports using the focal cerebralischemia injury model where deficiency in CX3CR1 sig-
naling in knockout mice decreased cortical neurodegener-
ation [16-18,29]. Because of the different injury model in
assessing the role of CX3CR1 in ischemic injury between
our study and those of others, the conflicting findings
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suggest that the protection afforded by this chemokine in
temporary occlusion (focal ischemia) may be more pro-
found compared to permanent occlusion (global ische-
mia). To our knowledge, our study is the first to report
the role of CX3CR1 on the chronic consequences of tran-
sient global cerebral ischemia.
Our data show that both fractalkine and CX3CR1 ex-
pression are significantly decreased in the hippocampus
during the post-recovery period following transient global
cerebral ischemia. These results are in contrast to earlier
reports that the ischemia-induced downregulation of frac-
talkine/CX3CR1 expression occurs within 24 h of injury
followed by an upregulation at 48 h to 7 days after ische-
mic injury [30]. The contradictory findings may be ex-
plained by the timing of measurement wherein reports to
date assessed fractalkine/CX3CR1 expression following
cerebral ischemia only up to 1 week after injury whereas
our study evaluated the ischemia-induced changes in frac-
talkine/CX3CR1 at more than 1 month after reperfusion.
It is possible that downregulation of fractalkine/CX3CR1
in the immediate hours to days after ischemic injury is a
compensatory response to allow for increased microglial
activation so that the brain can mount an inflammatory
response. But the subsequent upregulation of fractalkine/
CX3CR1 expression during the acute phase of ischemic
injury is a necessary response to regulate microglial over-
activation and control the inflammatory response to pre-
vent further tissue damage. By contrast, the decreased
fractalkine expression in the ischemic group seen in the
present study may be a reflection of the delayed neurode-
generation seen in transient global cerebral ischemia since
neurons constitutively synthesize this protein [8]. In
addition, the ischemia-induced decrease in CX3CR1 ex-
pression in our study may be due a compensatory receptor
downregulation in response to a reduction in the availabil-
ity of ligands.
In the current study we also show that transient global
cerebral ischemic can induce persistent neuroinflamma-
tion evidenced by elevated IL-1β and TNF-α weeks after
injury and these findings are consistent with previous re-
ports [8]. One of the effects of ischemic injury is neuro-
inflammation, which is an important part of ischemic
pathophysiology, especially in the context of reperfusion.
But, as widely reported, ischemia-reperfusion itself can
also set off numerous cascades of secondary injuries. Re-
active oxygen species are generated as well as numerous
processes involving delayed neuronal death, apoptosis,
and autophagy may still continue unabated [1,2]. Along
with these central responses, activation of peripheral im-
mune responses may also continue to occur leading to
persistent neuroinflammation [4]. Part of the inflamma-
tory process is microglial activation that happens within
minutes of ischemia onset (reviewed in [31]). Postischemic
microglial proliferation peaks at 48 to 72 h after cerebralAC
TE
D
ischemia and may last for several weeks after initial injury.
Upon activation, microglia undergo proliferation and mor-
phological change from a ramified to hypertrophic pheno-
type with thicker processes, producing inflammatory
mediators such as cytokines, chemokines, and growth fac-
tors. Traditionally, microglial activation would be viewed
as deleterious consequences in ischemic injury since over-
activated microglia can be neurotoxic by releasing reactive
oxygen species via NADPH oxidase [32]. But it is now in-
creasingly recognized that microglial activation may not
always be bad after cerebral ischemic injury since they can
also produce anti-inflammatory cytokines and growth fac-
tors depending on its activation state [33].
Microglial activation is not a univalent state, and at
least two activated phenotypes, ‘classically activated’
(also called M1) or ‘alternatively activated’ (also called
M2), have been identified. Inflammatory microglia (M1)
release a number of proinflammatory cytokines such as
TNF-α and IL-1β, reactive oxygen species, and nitrous
oxide [32]. While M2-activated microglial are consid-
ered less inflammatory because they are characterized
by reduced nitrous oxide production and increased pro-
duction of anti-inflammatory cytokines and neurotrophic
factors such as brain-derived neurotrophic factor, insulin-
like growth factor-1, and transforming growth factor-β.
Our data show clear evidence on the role of CX3CR1 on
determining the functional state of activated microglia fol-
lowing ischemic injury. That is, ischemic control animals
show increased OX-42 immunoreactivity and the pheno-
type of these microglial cells are mostly ramified and
hypertrophic in appearance and it is associated with eleva-
tions in the anti-inflammatory cytokines IL-4 and IL-10.
In contrast, inhibition of CX3CR1 function in ischemic
rats show increased ED-1 immunoreactivity and these
microglial cells are hypertrophic but mostly bushy and
ameboid in appearance associated with significant eleva-
tions in the pro-inflammatory cytokines, IL-1β and TNF-
α. It is important to understand the role of fractalkine/
CX3CR1 signaling microglial activation for its therapeutic
potential in modulating the duration and magnitude of
neuroinflammation following ischemic injury.
Our results also show that CX3CR1 deficiency worsens
the behavioral impairment induced by ischemic injury.
Silencing the expression of CX3CR1 exacerbates the
learning and memory deficits seen in the performance of
ischemic rats in the cued learning, discrimination learn-
ing, and delayed non-matching-to-sample tasks. Likewise,
silencing the expression of CX3CR1 in sham rats resulted
in impaired behavioral performance. The enhanced behav-
ioral deficit induced by CX3CR1 deficiency is accompan-
ied by increased proinflammatory cytokines and a change
in microglial morphology from ramified to bushy pheno-
type. Our findings on the ischemic animals are consistent
with previous reports that show CX3CR1 deficiency
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intensifies microglial activation, increases IL-1β expres-
sion, and worsens the behavioral deficits in the transgenic
mouse model of Alzheimer’s disease [14]. Similarly, our
data on cognitive impairment in the sham rats given
CX3CR1 siRNA are in line to a previous study that reports
behavioral impairment and decreased synaptic plasticity in
intact but CX3CR1 deficient mice [34]. Nonetheless, our
results are at odds with others that report better perform-
ance in the water maze in intact but CX3CR1 deficient
mice [11]. A possible explanation for the difference in
findings may be due to the behavioral testing used wherein
the previous report used the place learning and memory
tasks in the water maze whereas our study utilized three
tests with different complexity. That is, the place learning
task in the water maze may lack sufficient complexity to
detect subtle learning differences in normal animals, thus
the performance of both control and CX3CR1 deficient
groups will likely be affected by a ‘ceiling effect’. Taken to-
gether, our results suggest that CX3CR1 deficiency can re-
sult in cognitive impairment under both physiological
(sham animals) and pathological (ischemia animals) con-
ditions. However, the behavioral deficit resulting from
CX3CR1 deficiency in the sham rats is accompanied by el-
evations in IL-1β but not TNF-α suggesting the specific
role of IL-1β in cognitive function.
The present study provides important insight to un-
derstanding the involvement of CX3CR1 in the chronic
neuroinflammation and cognitive impairment as a conse-
quence of transient global cerebral ischemia. Although
there is substantial literature in the area of fractalkine/
CX3CR1 signaling in the brain, no consensus as to the
role of this signaling pathway as either neuroprotective or
neurodegenerative has been agreed upon. Furthermore
studies delineating the involvement of fractalkine/CX3CR1
during the acute phase and long-term recovery period after
ischemic injury are necessary to address the complexity of
this signaling pathway in neuropathology. As well, studies
on the role of fractalkine/CX3CR1 in neuropathology
must include assessment of behavioral outcomes to truly
understand the role and potential therapeutic value of this
unique chemokine/receptor duo.
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